Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor

Mohri, Hiroshi; Tanabe, Juichi; Ohtsuka, Minoru; Yoshida, Motoyuki; Motomura, Shigeki; Nishida, Sachiyo; Fujimura, Yoshihiro; Ōkubo, Takao

doi:10.1097/00001721-199509000-00010

Cited by 44 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include autoantibodies, either interfering with platelet [23][24][25][26][27][28] or collagen binding, [29][30][31] or increasing VWF clearance from the plasma. 32 Sequestration of high-molecular-weight (HMW) multimers was demonstrated in patients with hematologic disorders because of adsorption to myeloma cells or platelets, but also in reactive thrombocytosis.…”

Section: Pathogenesismentioning

confidence: 99%

How I treat the acquired von Willebrand syndrome

Tiede

Rand

Budde³

et al. 2011

Blood

293

330

View full text Add to dashboard Cite

Section: Pathogenesismentioning

confidence: 99%

How I treat the acquired von Willebrand syndrome

Tiede

Rand

Budde³

et al. 2011

Blood

293

330

View full text Add to dashboard Cite

“…The most frequently observed association is with dysproteinemias. These range from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell proliferative disorders such as Waldenstrom macroglobulinemia and multiple myeloma [106][107][108].…”

Section: Cause and Pathogenesismentioning

confidence: 99%

Platelet disorders

Manasa

Vani²

2015

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Thrombocytes or platelets are anucleated cells derived from megakaryocytes by process of megakaryopoiesis, with maturation time of 4-5 days. They are small and discoid in shape with size ranging from 2 to 4 μm. The platelet concentration in blood varies between 150, 000 and 400, 000 cells/μl of blood. They are involved in both hemostasis and wound healing. Hence, any abnormalities in platelets can lead to various bleeding disorders. Platelet disorders include thrombocythemia and thrombocytosis, thrombocytopenia and platelet dysfunction. Thrombocythemia and thrombocytosis are associated with increased platelet count because of overproduction of platelets. Thrombocytopenia includes decreased platelet count because of failed platelet production, increased sequestration of platelets in spleen, dilution of platelets and combination of these mechanisms. Platelet dysfunction can be because of intrinsic platelet defect or an extrinsic factor that alters the normal platelet function and can be hereditary or acquired. The following review provides a comprehensive overview of the above platelet disorders.

show abstract

“…As regards the lymphoproliferative disorders, monoclonal gammopathy of undetermined significance (MGUS) is the condition most frequently associated with aVWS [17][18][19][20][21][22][23]. aVWS is also associated with multiple myeloma [24][25][26][27][28][29], Waldenstrom macroglobulinaemia [30,31], chronic lymphocytic leukemia [32], hairy cell leukemia [33], and non-Hodgkin lymphoma [34][35][36]. Most cases of myeloproliferative disorders associated with aVWS are essential thrombocythemia [37][38][39][40][41][42][43][44][45][46][47], while polycythemia vera [48] and chronic myeloid leukemia [49][50][51] are less frequent.…”

Section: Associated Disorders and Pathogenic Mechanismsmentioning

confidence: 99%

Acquired von Willebrand syndrome: An update

Franchini

Lippi

2006

American J Hematol

View full text Add to dashboard Cite

Acquired von Willebrand syndrome (aVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD). However, unlike congenital VWD, it arises in individuals with no personal or family history of bleeding. aVWS occurs in association with a variety of underlying disorders, most frequently in lymphoproliferative disorders, myeloproliferative disorders, and cardiovascular diseases. Through an analysis of the more recent literature data, the pathophysiology and the clinical, laboratory, and therapeutic aspects of this syndrome are concisely reported in this review. Am. J. Hematol. 82:368-375, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor

Cited by 44 publications

References 0 publications

How I treat the acquired von Willebrand syndrome

How I treat the acquired von Willebrand syndrome

Platelet disorders

Acquired von Willebrand syndrome: An update

Contact Info

Product

Resources

About